Cardiol Therapeutics
CRDL
41 hedge funds and large institutions have $10.8M invested in Cardiol Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
4,883% more call options, than puts
Call options by funds: $897K | Put options by funds: $18K
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
17% more funds holding
Funds holding: 35 → 41 (+6)
2.25% less ownership
Funds ownership: 10.07% → 7.81% (-2.3%)
8% less capital invested
Capital invested by funds: $11.7M → $10.8M (-$912K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$350K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$212K |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
+$165K |
| 4 |
LSA
Lion Street Advisors
Austin,
Texas
|
+$129K |
| 5 |
UBS AM
Chicago,
Illinois
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$3.48M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$72.6K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$51.8K |
| 4 |
Two Sigma Advisers
New York
|
-$29.9K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$26.8K |
CRDL Hedge Fund Activity: Q2 2024 in Review
41 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q2 2024, worth a combined $10.8M — down 7.8% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CRDL positions and 5 closed out — a net gain of 7 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $350K. The largest seller was MMCAP International, cutting an estimated $3.48M.
- 41 institutional investors held Cardiol Therapeutics (CRDL) as of Q2 2024, up from 35 in Q1 2024.
- Funds reported $10.8M of Cardiol Therapeutics stock for Q2 2024, down 7.8% quarter-over-quarter.
- 12 funds opened new Cardiol Therapeutics positions in Q2 2024 and 5 closed out, a net change of +7 holders.
- The largest Cardiol Therapeutics buyer in Q2 2024 was AdvisorShares Investments, an estimated $350K added.
- The largest Cardiol Therapeutics seller in Q2 2024 was MMCAP International, an estimated $3.48M sold.
Based on aggregated 13F filings for Q2 2024.